CN111138527B - 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 - Google Patents
抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 Download PDFInfo
- Publication number
- CN111138527B CN111138527B CN201811310292.3A CN201811310292A CN111138527B CN 111138527 B CN111138527 B CN 111138527B CN 201811310292 A CN201811310292 A CN 201811310292A CN 111138527 B CN111138527 B CN 111138527B
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- monoclonal antibody
- ser
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000288 Glycoproteins Proteins 0.000 title claims abstract description 48
- 102000003886 Glycoproteins Human genes 0.000 title claims abstract description 48
- 241001115402 Ebolavirus Species 0.000 title claims description 36
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 7
- 108091033319 polynucleotide Proteins 0.000 claims 7
- 239000002157 polynucleotide Substances 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000027455 binding Effects 0.000 abstract description 36
- 230000003472 neutralizing effect Effects 0.000 abstract description 20
- 241000700605 Viruses Species 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 238000000338 in vitro Methods 0.000 abstract description 9
- 210000001163 endosome Anatomy 0.000 abstract description 8
- 241001112090 Pseudovirus Species 0.000 abstract description 7
- 238000006386 neutralization reaction Methods 0.000 abstract description 6
- 238000002648 combination therapy Methods 0.000 abstract description 5
- 230000009870 specific binding Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 27
- 108090000623 proteins and genes Proteins 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 21
- 238000005406 washing Methods 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 108091026890 Coding region Proteins 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108700016947 Bos taurus structural-GP Proteins 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 238000007857 nested PCR Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 210000001806 memory b lymphocyte Anatomy 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000012257 pre-denaturation Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101001124388 Homo sapiens NPC intracellular cholesterol transporter 1 Proteins 0.000 description 4
- 241000880493 Leptailurus serval Species 0.000 description 4
- 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 description 4
- 229940125644 antibody drug Drugs 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000034217 membrane fusion Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108091034057 RNA (poly(A)) Proteins 0.000 description 3
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229940126580 vector vaccine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OHLLDUNVMPPUMD-DCAQKATOSA-N Cys-Leu-Val Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N OHLLDUNVMPPUMD-DCAQKATOSA-N 0.000 description 2
- 108010088468 Ebola virus envelope glycoprotein Proteins 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- WGYHAAXZWPEBDQ-IFFSRLJSSA-N Glu-Val-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WGYHAAXZWPEBDQ-IFFSRLJSSA-N 0.000 description 2
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 2
- BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 2
- VUBIPAHVHMZHCM-KKUMJFAQSA-N Leu-Tyr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CC=C(O)C=C1 VUBIPAHVHMZHCM-KKUMJFAQSA-N 0.000 description 2
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 2
- CGBYDGAJHSOGFQ-LPEHRKFASA-N Pro-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@@H]2CCCN2 CGBYDGAJHSOGFQ-LPEHRKFASA-N 0.000 description 2
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 2
- 241000394658 Prymnesium kappa Species 0.000 description 2
- 241001115394 Reston ebolavirus Species 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 2
- 241001115376 Sudan ebolavirus Species 0.000 description 2
- 108090001109 Thermolysin Proteins 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- 108010049041 glutamylalanine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010077112 prolyl-proline Proteins 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- MPLOSMWGDNJSEV-WHFBIAKZSA-N Ala-Gly-Asp Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O MPLOSMWGDNJSEV-WHFBIAKZSA-N 0.000 description 1
- SUMYEVXWCAYLLJ-GUBZILKMSA-N Ala-Leu-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O SUMYEVXWCAYLLJ-GUBZILKMSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 1
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 1
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 1
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 1
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- ZDILXFDENZVOTL-BPNCWPANSA-N Ala-Val-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZDILXFDENZVOTL-BPNCWPANSA-N 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 1
- RKRSYHCNPFGMTA-CIUDSAMLSA-N Arg-Glu-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O RKRSYHCNPFGMTA-CIUDSAMLSA-N 0.000 description 1
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 1
- OTZMRMHZCMZOJZ-SRVKXCTJSA-N Arg-Leu-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O OTZMRMHZCMZOJZ-SRVKXCTJSA-N 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- NVGWESORMHFISY-SRVKXCTJSA-N Asn-Asn-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NVGWESORMHFISY-SRVKXCTJSA-N 0.000 description 1
- SRUUBQBAVNQZGJ-LAEOZQHASA-N Asn-Gln-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)N)N SRUUBQBAVNQZGJ-LAEOZQHASA-N 0.000 description 1
- WQLJRNRLHWJIRW-KKUMJFAQSA-N Asn-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)N)N)O WQLJRNRLHWJIRW-KKUMJFAQSA-N 0.000 description 1
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- QNNBHTFDFFFHGC-KKUMJFAQSA-N Asn-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QNNBHTFDFFFHGC-KKUMJFAQSA-N 0.000 description 1
- MJIJBEYEHBKTIM-BYULHYEWSA-N Asn-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MJIJBEYEHBKTIM-BYULHYEWSA-N 0.000 description 1
- HSWYMWGDMPLTTH-FXQIFTODSA-N Asp-Glu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HSWYMWGDMPLTTH-FXQIFTODSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- WNGZKSVJFDZICU-XIRDDKMYSA-N Asp-Leu-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N WNGZKSVJFDZICU-XIRDDKMYSA-N 0.000 description 1
- XFQOQUWGVCVYON-DCAQKATOSA-N Asp-Met-His Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XFQOQUWGVCVYON-DCAQKATOSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 1
- JSNWZMFSLIWAHS-HJGDQZAQSA-N Asp-Thr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O JSNWZMFSLIWAHS-HJGDQZAQSA-N 0.000 description 1
- KNDCWFXCFKSEBM-AVGNSLFASA-N Asp-Tyr-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O KNDCWFXCFKSEBM-AVGNSLFASA-N 0.000 description 1
- 239000004364 Benzylated hydrocarbon Substances 0.000 description 1
- 241000884921 Bundibugyo ebolavirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 1
- YMBAVNPKBWHDAW-CIUDSAMLSA-N Cys-Asp-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N YMBAVNPKBWHDAW-CIUDSAMLSA-N 0.000 description 1
- WVLZTXGTNGHPBO-SRVKXCTJSA-N Cys-Leu-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O WVLZTXGTNGHPBO-SRVKXCTJSA-N 0.000 description 1
- KSMSFCBQBQPFAD-GUBZILKMSA-N Cys-Pro-Pro Chemical compound SC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 KSMSFCBQBQPFAD-GUBZILKMSA-N 0.000 description 1
- NDNZRWUDUMTITL-FXQIFTODSA-N Cys-Ser-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NDNZRWUDUMTITL-FXQIFTODSA-N 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 101001120060 Dictyostelium discoideum Protein P80 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229940124722 Ebola vaccine Drugs 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 101150117028 GP gene Proteins 0.000 description 1
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 1
- WLODHVXYKYHLJD-ACZMJKKPSA-N Gln-Asp-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N WLODHVXYKYHLJD-ACZMJKKPSA-N 0.000 description 1
- NVEASDQHBRZPSU-BQBZGAKWSA-N Gln-Gln-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O NVEASDQHBRZPSU-BQBZGAKWSA-N 0.000 description 1
- ZNZPKVQURDQFFS-FXQIFTODSA-N Gln-Glu-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZNZPKVQURDQFFS-FXQIFTODSA-N 0.000 description 1
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 1
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 1
- XUMFMAVDHQDATI-DCAQKATOSA-N Gln-Pro-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUMFMAVDHQDATI-DCAQKATOSA-N 0.000 description 1
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 1
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 1
- BETSEXMYBWCDAE-SZMVWBNQSA-N Gln-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N BETSEXMYBWCDAE-SZMVWBNQSA-N 0.000 description 1
- SGVGIVDZLSHSEN-RYUDHWBXSA-N Gln-Tyr-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(O)=O SGVGIVDZLSHSEN-RYUDHWBXSA-N 0.000 description 1
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 1
- AVZHGSCDKIQZPQ-CIUDSAMLSA-N Glu-Arg-Ala Chemical compound C[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O AVZHGSCDKIQZPQ-CIUDSAMLSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 1
- MWMJCGBSIORNCD-AVGNSLFASA-N Glu-Leu-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O MWMJCGBSIORNCD-AVGNSLFASA-N 0.000 description 1
- AAJHGGDRKHYSDH-GUBZILKMSA-N Glu-Pro-Gln Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O AAJHGGDRKHYSDH-GUBZILKMSA-N 0.000 description 1
- BPCLDCNZBUYGOD-BPUTZDHNSA-N Glu-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 BPCLDCNZBUYGOD-BPUTZDHNSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 1
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 1
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 1
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 1
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- SYOJVRNQCXYEOV-XVKPBYJWSA-N Gly-Val-Glu Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SYOJVRNQCXYEOV-XVKPBYJWSA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- FYVHHKMHFPMBBG-GUBZILKMSA-N His-Gln-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FYVHHKMHFPMBBG-GUBZILKMSA-N 0.000 description 1
- HVCRQRQPIIRNLY-IUCAKERBSA-N His-Gln-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N HVCRQRQPIIRNLY-IUCAKERBSA-N 0.000 description 1
- TTYKEFZRLKQTHH-MELADBBJSA-N His-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O TTYKEFZRLKQTHH-MELADBBJSA-N 0.000 description 1
- TVMNTHXFRSXZGR-IHRRRGAJSA-N His-Lys-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O TVMNTHXFRSXZGR-IHRRRGAJSA-N 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000193096 Human adenovirus B3 Species 0.000 description 1
- MKWSZEHGHSLNPF-NAKRPEOUSA-N Ile-Ala-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N MKWSZEHGHSLNPF-NAKRPEOUSA-N 0.000 description 1
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 1
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- MJTOYIHCKVQICL-ULQDDVLXSA-N Leu-Met-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N MJTOYIHCKVQICL-ULQDDVLXSA-N 0.000 description 1
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 1
- DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- DAYQSYGBCUKVKT-VOAKCMCISA-N Leu-Thr-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DAYQSYGBCUKVKT-VOAKCMCISA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- QESXLSQLQHHTIX-RHYQMDGZSA-N Leu-Val-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QESXLSQLQHHTIX-RHYQMDGZSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 1
- NTBFKPBULZGXQL-KKUMJFAQSA-N Lys-Asp-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTBFKPBULZGXQL-KKUMJFAQSA-N 0.000 description 1
- RFQATBGBLDAKGI-VHSXEESVSA-N Lys-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCCN)N)C(=O)O RFQATBGBLDAKGI-VHSXEESVSA-N 0.000 description 1
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
- QLFAPXUXEBAWEK-NHCYSSNCSA-N Lys-Val-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O QLFAPXUXEBAWEK-NHCYSSNCSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- RKIIYGUHIQJCBW-SRVKXCTJSA-N Met-His-Glu Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O RKIIYGUHIQJCBW-SRVKXCTJSA-N 0.000 description 1
- FWAHLGXNBLWIKB-NAKRPEOUSA-N Met-Ile-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCSC FWAHLGXNBLWIKB-NAKRPEOUSA-N 0.000 description 1
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108700018419 Niemann-Pick C1 Proteins 0.000 description 1
- LGBVMDMZZFYSFW-HJWJTTGWSA-N Phe-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC1=CC=CC=C1)N LGBVMDMZZFYSFW-HJWJTTGWSA-N 0.000 description 1
- JOXIIFVCSATTDH-IHPCNDPISA-N Phe-Asn-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N JOXIIFVCSATTDH-IHPCNDPISA-N 0.000 description 1
- ZLGQEBCCANLYRA-RYUDHWBXSA-N Phe-Gly-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O ZLGQEBCCANLYRA-RYUDHWBXSA-N 0.000 description 1
- AAERWTUHZKLDLC-IHRRRGAJSA-N Phe-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O AAERWTUHZKLDLC-IHRRRGAJSA-N 0.000 description 1
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 1
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- MHHQQZIFLWFZGR-DCAQKATOSA-N Pro-Lys-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O MHHQQZIFLWFZGR-DCAQKATOSA-N 0.000 description 1
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 1
- HZWAHWQZPSXNCB-BPUTZDHNSA-N Ser-Arg-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HZWAHWQZPSXNCB-BPUTZDHNSA-N 0.000 description 1
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 1
- UGJRQLURDVGULT-LKXGYXEUSA-N Ser-Asn-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UGJRQLURDVGULT-LKXGYXEUSA-N 0.000 description 1
- BTPAWKABYQMKKN-LKXGYXEUSA-N Ser-Asp-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O BTPAWKABYQMKKN-LKXGYXEUSA-N 0.000 description 1
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 1
- JWOBLHJRDADHLN-KKUMJFAQSA-N Ser-Leu-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JWOBLHJRDADHLN-KKUMJFAQSA-N 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- XSLXHSYIVPGEER-KZVJFYERSA-N Thr-Ala-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O XSLXHSYIVPGEER-KZVJFYERSA-N 0.000 description 1
- SXAGUVRFGJSFKC-ZEILLAHLSA-N Thr-His-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SXAGUVRFGJSFKC-ZEILLAHLSA-N 0.000 description 1
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- JMBRNXUOLJFURW-BEAPCOKYSA-N Thr-Phe-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N)O JMBRNXUOLJFURW-BEAPCOKYSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- XGFGVFMXDXALEV-XIRDDKMYSA-N Trp-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N XGFGVFMXDXALEV-XIRDDKMYSA-N 0.000 description 1
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- QJBWZNTWJSZUOY-UWJYBYFXSA-N Tyr-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N QJBWZNTWJSZUOY-UWJYBYFXSA-N 0.000 description 1
- QYSBJAUCUKHSLU-JYJNAYRXSA-N Tyr-Arg-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O QYSBJAUCUKHSLU-JYJNAYRXSA-N 0.000 description 1
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 1
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 1
- JJNXZIPLIXIGBX-HJPIBITLSA-N Tyr-Ile-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N JJNXZIPLIXIGBX-HJPIBITLSA-N 0.000 description 1
- GZUIDWDVMWZSMI-KKUMJFAQSA-N Tyr-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GZUIDWDVMWZSMI-KKUMJFAQSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- GPLTZEMVOCZVAV-UFYCRDLUSA-N Tyr-Tyr-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 GPLTZEMVOCZVAV-UFYCRDLUSA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- SQUMHUZLJDUROQ-YDHLFZDLSA-N Tyr-Val-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O SQUMHUZLJDUROQ-YDHLFZDLSA-N 0.000 description 1
- CGGVNFJRZJUVAE-BYULHYEWSA-N Val-Asp-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CGGVNFJRZJUVAE-BYULHYEWSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
- OACSGBOREVRSME-NHCYSSNCSA-N Val-His-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(O)=O OACSGBOREVRSME-NHCYSSNCSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- XPKCFQZDQGVJCX-RHYQMDGZSA-N Val-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N)O XPKCFQZDQGVJCX-RHYQMDGZSA-N 0.000 description 1
- FMQGYTMERWBMSI-HJWJTTGWSA-N Val-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](C(C)C)N FMQGYTMERWBMSI-HJWJTTGWSA-N 0.000 description 1
- KISFXYYRKKNLOP-IHRRRGAJSA-N Val-Phe-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)O)N KISFXYYRKKNLOP-IHRRRGAJSA-N 0.000 description 1
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 1
- SDHZOOIGIUEPDY-JYJNAYRXSA-N Val-Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 SDHZOOIGIUEPDY-JYJNAYRXSA-N 0.000 description 1
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 1
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 1
- GVNLOVJNNDZUHS-RHYQMDGZSA-N Val-Thr-Lys Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O GVNLOVJNNDZUHS-RHYQMDGZSA-N 0.000 description 1
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010038850 arginyl-isoleucyl-tyrosine Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000013357 binding ELISA Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000023368 generalized pustular psoriasis Diseases 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 1
- 108010091871 leucylmethionine Proteins 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 238000007860 single-cell PCR Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 108010071097 threonyl-lysyl-proline Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 108010079202 tyrosyl-alanyl-cysteine Proteins 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- 108010009962 valyltyrosine Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种抗埃博拉病毒糖蛋白GP1亚基的单克隆抗体4F1,所述抗体具有独特的CDR区,与EBOV GP1亚基具有特异性的结合活性,并且结合稳定,不受次级内体低pH环境的影响,为其发挥中和作用提供了基础。与对照抗体相比,4F1在体外可有效地中和EBOV假病毒。4F1中和活性随着抗体浓度的升高而增强,在1μg/mL的浓度下即可对EBOV实现100%的保护。本发明提供的单克隆抗体4F1与MIL77‑3等对照抗体都结合于GP1亚基,且竞争结合,但4F1具有体外中和活性,而其他抗体则不具有中和活性,提示4F1具有与其他结合于GP2亚基的中和抗体组成鸡尾酒组合疗法的潜力。
Description
技术领域
本发明公开了一种抗体,属于多肽技术领域。
背景技术
埃博拉病毒(Ebola virus,EBOV)能在人类和非人灵长类体内引发急性严重出血热病,是迄今发现的致死率最高的病毒之一,致死率高达90%,可直接通过接触传播,具有极强的传染性和致死率。埃博拉病毒包膜表面上的糖蛋白(Glycoprotein,GP)刺突几乎介导了病毒进入细胞的所有环节,因此埃博拉GP是一个重要的病毒中和抗体作用靶点。埃博拉病毒GP基因被加工成两种蛋白,一种是分泌的非结构型GP(secreted glycoprotein,sGP);另一种是结构型GP。埃博拉GP首先作为一个多肽被合成,接着被Furin酶酶切成为GP1(1-501位氨基酸)和GP2(502-676位氨基酸)亚基,两个亚基通过二硫键相连接,形成的三聚体由GP2内部的跨膜区固定在于包膜表面。GP1包含黏蛋白(Mucin)、聚糖帽(Glycan cap)、头部(Head)、基部(Base)等结构域。Furin酶切后形成的GP结构并不能直接激发埃博拉病毒与宿主细胞膜融合过程的发生。埃博拉病毒进入体内后,与细胞膜表面受体结合,但是这些宿主细胞膜表面的粘附因子,并不是真正的埃博拉病毒发生膜融合进入宿主细胞的受体。病毒结合于细胞表面粘附因子后,由网格蛋白介导胞吞和胞饮,发生初级和次级核内体的运输。GP在核内体中被组蛋白酶B和组蛋白酶L酶切,去除GP1上包括黏蛋白和聚糖帽在内的60%的氨基酸,形成激活态GP(primed GP,GPcl),此时激活了决定性的膜融合过程的发生。GPcl与内体膜蛋白Niemann-Pick C1(NPC1)结合发生膜融合,从而使病毒RNA进入胞质完成病毒基因组复制和转录,新病毒蛋白合成后组装成子代病毒颗粒,并从宿主细胞表面出芽。内体膜蛋白NPC1是EBOV感染的必不可少的宿主感染因子。
埃博拉病毒被美国NIH和CDC列为A类生物剂/生物恐怖剂,将其归为对国家安全和公众健康存在重大隐患和风险的病原体之一,目前仍没有获批的预防或治疗埃博拉病毒的药物。1967年埃博拉病毒被发现后,共经历了12次较大规模的传播。2014年西非爆发了历史上最大规模、最难控制的埃博拉疫情,经鉴定为扎伊尔型埃博拉病毒,此次疫情造成1万多例死亡和2.5万多例感染(根据WHO 2016年2月17日发布的埃博拉疫情报告),疫情首次传播到非洲大陆以外,在世界范围内引起了极大的恐慌。公众和当局的高度关注快速推进了埃博拉疫苗和抗病毒药物的研究。
国内外迅速开展了几个有前景的埃博拉疫苗临床试验:大猩猩腺病毒3型载体疫苗、腺病毒5型载体疫苗、水疱性口炎病毒载体疫苗等。不可否认地,发展有效的预防类药物是一个重要的目标,并且预防措施被认为可以挽救大量的生命,然而疫苗在某些情况下难以发挥作用,比如:1)宿主个体可能存在差异(如年长者、年幼者及免疫受损者的免疫能力薄弱);2)疫苗长时间免疫后免疫效果逐渐减弱;3)疫苗激发宿主的免疫无法抵抗高剂量的埃博拉病毒暴露;4)大部分病人仅在出现埃博拉病毒感染信号后才寻求药物帮助,疫苗在短暂的治疗窗口期内难以激发宿主有效的免疫应答。因此,在开发疫苗的进程中埃博拉病毒病治疗药物的研发同样不容忽视。目前埃博拉病毒中和抗体可能通过三种途径发挥保护作用:1)阻断GP被组织蛋白酶酶切水解;2)阻断激活态GP与NPC1受体的结合;3)影响与NPC1受体结合后到膜融合前GP的变构过程。其中,前两种途径已有文献证实,第三种途径为部分文献的推测,尚无直接证据。
尽管目前没有批准的埃博拉病毒病治疗药物,但是有一些实验型抗埃博拉病毒药物正在研究当中,包括小干扰RNA、反义寡核苷酸、核苷酸类似物、抗体等。2018年5月,埃博拉疫情在刚果民主共和国再一次爆发,截止到8月12日,造成57人感染,41人死亡。在此次疫情爆发后,WHO批准了5种处于研究阶段的药物,可以被用于应急治疗埃博拉病毒病,其中包括3种抗体药物(Zmapp、REGN3470-3471-3479和mAb114)和2种小分子药物(Remdesivir和Favipiravir)。其中,由三株单克隆抗体混合而成的抗体药物“Zmapp”及其优化株“MIL77”在2014年西非埃博拉疫情爆发期间,成功挽救了多人的生命,其效果和治疗窗口期长度远超于其他种类的抗病毒药物,大大提高了药物安全性和患者治愈率,给了人们极大的鼓舞。应用抗体药物治疗丝状病毒病引起了世界范围内的关注,成为埃博拉病毒病治疗药物研究领域的热点。
Zmapp是由烟草***表达的三株人鼠嵌合单抗(c2G4、c4G7、c13C6)组成的鸡尾酒治疗策略,其中c2G4(表位为C511,N550,G553,C556)和c4G7(表位为C511,D552,C556)结合于GP2亚基,表位存在交叠;c13C6(表位为T270,K272)以近似垂直的角度结合于聚糖帽区域。MIL77是优化于Zmapp的抗体组合,MIL77-1/-2/-3分别含有c2G4、c4G7和c13C6的可变区,其骨架区经人源化改造后表达于CHO细胞。MIL77-1和ML77-3两株抗体的鸡尾酒组合疗法在感染72小时后能够对非人灵长类起到100%的保护活性。
鸡尾酒组合疗法所显示的优异效果为埃博拉病毒病的治疗带来了新的启示,研发能够抗独特抗原表位的抗埃博拉病毒单克隆抗体成为本领域的一大技术需求,因为如果具有了更多的、不同于现有技术已经出现的抗独特抗原表位的抗埃博拉病毒单克隆抗体,则对于埃博拉病毒病的治疗方案就有了更多的选择,尤其是鸡尾酒组合制剂的方案设计。因此,本发明的目的就是提供一种能够针对独特抗原表位的抗埃博拉病毒糖蛋白的单克隆抗体,进而提供其在制备埃博拉病毒病治疗药物中的应用。
发明内容
基于上述目的,本发明首先提供了一种抗埃博拉病毒糖蛋白GP2亚基的单克隆抗体4F1,所述抗体轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.1的第27-32、50-52和89-97位氨基酸序列所示,所述抗体重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.5的第26-33、51-57和96-107位氨基酸序列所示。
在一个优选的实施方案中,所述抗体轻链可变区的氨基酸序列如SEQ ID NO.1所示,所述抗体重链可变区的氨基酸序列如SEQ ID NO.5所示。
在一个更为优选的实施方案中,所述抗体轻链恒定区的氨基酸序列如SEQ IDNO.3所示,所述抗体重链恒定的氨基酸序列如SEQ ID NO.7所示。
其次,本发明还提供了一种上述单克隆抗体轻链和重链的基因编码序列,所述抗体的轻链可变区的基因编码序列由SEQ ID NO.2所示,所述抗体的重链可变区的基因编码序列由SEQ ID NO.6所示。
在一个优选的实施方案中,所述抗体的轻链恒定区的基因编码序列由SEQ IDNO.4所示,所述抗体的重链恒定区的基因编码序列由SEQ ID NO.8所示。
再次,本发明提供了一种能够表达上述编码单克隆抗体重链和/或轻链的基因编码序列的功能元件。
在一个优选的实施方案中,所述功能元件为线性表达框。
又次,本发明提供了一种含有上述线性表达框的宿主细胞,所述细胞为293T细胞。
最后,本发明提供了上述的单克隆抗体在制备埃博拉病毒病治疗药物中的应用。
在一个优选的实施方案中,所述单克隆抗体作为埃博拉病毒病鸡尾酒疗法制剂中的组分使用。
本发明提供的抗埃博拉病毒包膜糖蛋白的单克隆抗体4F1具有独特的CDR区,与EBOV GP1亚基具有特异性的结合活性,并且结合稳定,不受次级内体低pH环境的影响,为其发挥中和作用提供了基础。与对照抗体相比,4F1在体外可有效地中和EBOV假病毒。4F1中和活性随着抗体浓度的升高而增强,在1μg/mL的浓度下即可对EBOV实现100%的保护。本发明提供的4F1与MIL77-3等对照抗体都结合于GP1亚基,且竞争结合,但4F1具有体外中和活性,而其他抗体则不具有中和活性,提示4F1具有与其他结合于GP2亚基的中和抗体组成鸡尾酒组合疗法的潜力。
附图说明
图1.流式分选记忆B细胞结果图;
图2.巢式PCR扩增抗体基因的电泳鉴定图谱;
图3.线性表达框的拼接顺序示意图;
图4.抗体结合力筛选示意图;
图5. 4F1抗体与四种抗原结合活性曲线图;
图6. 4F1抗体与不同假病毒的中和活性曲线图;
图7.截短型GP构建示意图;
图8. 4F1与各截短型抗原的结合活性曲线图;
图9. 4F1与各截短型抗原的结合活性曲线图;
图10.抗体之间的竞争结合值示意图;
图11. 2G1与GP在不同pH下的结合活性曲线图。
具体实施方式
下面结合具体实施例来进一步描述本发明,本发明的优点和特点将会随着描述而更为清楚。但这些实施例仅是范例性的,并不对本发明的保护范围构成任何限制。
实施例1.抗体制备
1.血液样品的采集
在获得知情同意书后,采集重组埃博拉疫苗临床试验受试者第二次免疫28天后血液样品5mL,用于后续实验。
2.FITC标记蛋白GPdM
需要通过荧光标记的抗原来分选特异的记忆B细胞,FITC标记截短型抗原蛋白GPdM方法如下:
1)Fluorescein Isothiocyanate_FITC(SIGMA,F4274)溶于DMSO,浓度为20mg/mL。
2)取100μL GPdM(3.3mg/mL),加缓冲液(pH9.6碳酸盐缓冲液)至400μL。
3)加8μL FITC至GPdM溶液中,4℃避光孵育3h。
4)用50kD的离心浓缩管对溶液加PBS换液,直到滤过液为透明无色。将标记好的蛋白用锡箔纸包好,4℃存放待用。
3.流式分选记忆B细胞
将采集的血样利用Ficoll密度梯度离心法分离PBMC,过程如下:
1)取新鲜抗凝全血,EDTA抗凝。用等体积PBS稀释全血。
2)在离心管中加入一定体积的分离液,将稀释后的血样平铺到分离液液面上方,保持两液面界面清晰。分离液、抗凝未经稀释全血、PBS(或生理盐水)体积为1:1:1。
3)配平,室温,水平转子800g,加速度3acc,离心30min。
4)离心结束后,管底是红细胞,中间层是分离液,最上层是血浆/组织匀浆层,血浆层与分离液层之间是一层薄且较致密的白膜,即:单个核细胞(包括淋巴细胞和单核细胞)层。小心吸取白膜层到另一离心管中。
5)用PBS稀释到一定体积,颠倒混匀。室温,水平转子300g,离心10min,弃上清。重复洗涤2次。
6)用PBS将淋巴细胞重悬备用。
7)将用来分选的细胞计数,取1×106个细胞,体积为100μL,加入下表推荐量的6种荧光染料,4℃避光孵育1h。
8)使用含2%FBS的PBS重复洗涤2-3次,400μL FPBS重悬,用40μm细胞筛去除细胞团,4℃避光保存供分选。
9)使用细胞分选仪(SONY,SH800S)分选GP特异的单个记忆B细胞。分选策略为:IgG+/CD3-/CD38-/CD19+/CD27+/GPdM+,直接将单个浆细胞分选至96孔板中,96孔板中每孔含有5U RNA酶抑制剂及19.8μL去RNA酶的水中,-80℃保存。图1是细胞分选结果图,方框圈出部分的细胞特征为IgG+/CD3-/CD38-/CD19+/CD27+/GPdM+,即期望的GP特异性记忆B细胞。
4.单细胞PCR扩增全人源单抗
1)反转录PCR
分选得到80个GPdM特异的记忆B细胞,向每个反应体系中同时加入以下全部的针对重链H、κ轻链、λ轻链各亚型的特异引物(引物序列见表1)。
表1反转录PCR引物
PCR反应体系中包含:5×缓冲液6μL、dNTP 1.2μL、反转录酶1.2μL、引物如上、模板为单细胞,水补齐至30μL。
PCR反应条件为:50℃反转录30min,95℃预变性15min,接着95℃40s,55℃30s,72℃1min,40个循环,最后72℃延伸10min。
2)巢式PCR
以反转录产物为模板,分别进行3次巢式PCR反应扩增H、κ、λ(引物序列见表2),具体过程如下:
表2巢式PCR引物
PCR反应体系中包含:10×缓冲液2.5μL、10mM dNTP 0.5μL、DNA聚合酶0.25μL、引物如上、模板为反转录产物1μL、水补齐至25μL。
PCR反应条件为:94℃预变性4min,接着94℃30s,57℃30s,72℃45min,40个循环,最后72℃延伸10min。
3)琼脂糖凝胶电泳
一个单细胞中重链和轻链基因均扩增成功的克隆,被认为是配对成功的克隆。取5μL巢式PCR扩增产物经1%琼脂糖凝胶电泳后,取配对的阳性克隆进行测序,测序获得的抗体可变区序列用Vector NTI软件及IMGT网站进行分析,并进行抗体蛋白表达和功能验证。图2是对H、κ、λ三种链基因的巢式PCR扩增后琼脂糖凝胶电泳的鉴定图谱,只有当重链和轻链可变区基因从同一个记忆B细胞中扩增获得时,认为是自然配对的抗体基因,并将对应巢式PCR产物测序做进一步研究。
5.线性表达框表达抗体
通过上述反转录反应,单细胞克隆中获得了13个配对的抗体序列,如果采用传统的克隆表达方法费时费力,通过构建线性表达框的方法可以快速表达抗体。该方法的基本原理是直接通过重叠延伸PCR将启动子序列(GENBANK登记号:X03922.1)、抗体前导肽的编码序列、抗体可变区(从单细胞中扩增获得)、抗体恒定区(生工生物合成)、多聚A尾(GENBANK登记号:X03896.1)连接起来,将该线性形式的DNA转染进入细胞中进行抗体表达。
具体过程如下:
1)以pSec Tag2(Invitrogen)为模板,扩增启动子-前导序列片段、多聚A尾片段。
扩增启动子-前导序列片段的PCR反应体系中包含:模板质粒pSec Tag2(Invitrogen)1ng,10×缓冲液5μL、10mM dNTP 1μL、DNA聚合酶0.5μL、引物5'CMV-FORWARD(CGATGTACGGGCCAGATATACGCGTTG)、引物3'leader-sequence(GTCACCAGTGGAACCTGGAACCCA)、水补齐至50μL。
扩增多聚A尾片段的PCR反应体系中包含:模板质粒pSec Tag2(Invitrogen)1ng,10×缓冲液5μL、10mM dNTP 1μL、DNA聚合酶0.5μL、引物5'POLY(A)(GCCTCGACTGTGCCTTCTAGTTGC)、引物3'POLY(A)(TCCCCAGCATGCCTGCTATTGTCT)、水补齐至50μL。
PCR反应条件为:94℃预变性4min,接着94℃30s,60℃30s,72℃1min,30个循环,最后72℃延伸10min。
2)扩增抗体恒定区
H链恒定区PCR体系中包含:重链恒定区模板10ng、10×缓冲液5μL、10mM dNTP 1μL、DNA聚合酶0.5μL、引物5'CH(ACCAAGGGCCCATCGGTCTTCCCC)、引物3'CH(GCAACTAGAAGGCACAGTCGAGGCTTTACCCGGAGACAGGGA)、水补齐至50μL。
κ链恒定区PCR体系中包含:κ链恒定区模板10ng、10×缓冲液5μL、10mM dNTP 1μL、DNA聚合酶0.5μL、引物5'Cκ(ACTGTGGCTGCACCATCTGTCTTC)、引物3'Cκ(GCAACTAGAAGGCACAGTCGAGGCACACTCTCCCCTGTTGAAGCT)、水补齐至50μL。
λ链恒定区PCR体系中包含:λ链恒定区模板10ng、10×缓冲液5μL、10mM dNTP 1μL、DNA聚合酶0.5μL、引物5'Cλ(GAGGAGCTTCAAGCCAACAAGGCCACA)、引物3'Cλ(GCAACTAGAAGGCACAGTCGAGGCTGAACATTCTGTAGGGGCCAC)、水补齐至50μL。
PCR反应条件为:94℃预变性4min,接着94℃30s,60℃60s,72℃3min,30个循环,最后72℃延伸10min。
3)扩增抗体可变区
PCR体系中包含:模板为反转录PCR产物10ng,10×缓冲液5μL,10mM dNTP 1μL,DNA聚合酶0.5μL,引物如表3中所示(将重链和轻链引物分别混合后加入体系中),水补齐至50μL。
PCR反应条件为:94℃预变性4min,接着94℃30s,60℃30s,72℃3min,30个循环,最后72℃延伸10min。
表3.线性表达框构建PCR引物
4)PCR产物回收纯化:将以上PCR产物经1%的琼脂糖凝胶电泳后,切胶并使用OMEGA公司回收试剂盒回收。
5)分别扩增重链和轻链的线性表达框
线性表达框的拼接顺序示意图如图3所示。图3中,A为H链线性表达框,B为κ链线性表达框,C为λ链线性表达框。
PCR反应体系中包括:
模板:纯化后的启动子-前导序列片段10ng、重链/轻链可变区片段10ng、重链/轻链恒定区片段10ng、多聚A尾片段10ng,10×缓冲液2.5μL、10mM dNTP 0.5μL、DNA聚合酶0.25μL、引物5'CMV-FORWARD(CGATGTACGGGCCAGATATACGCGTTG)和3'POLY(A)(TCCCCAGCATGCCTGCTATTGTCT)、水补齐至25μL。
PCR反应条件为:94℃预变性4min,接着94℃30s,60℃30s,72℃3min,30个循环,最后72℃延伸10min。
6)PCR产物回收纯化:PCR反应产物直接用OMEGA公司回收试剂盒回收。
7)DNA定量:用Nano(GE Healthcare)对PCR回收产物进行定量。
8)细胞接种:将293T细胞以2×105/mL接种于24孔细胞培养板中,在含有5%CO2的细胞温箱中,37℃培养过夜。
9)细胞共转染:次日,向200μL无血清的MEM培养基中,加入构建成功的重链和轻链线性表达框PCR产物各1μg,混匀后加入4μL转染试剂Turbofect(Thermo Scientific,R0531),共同孵育15-20min后逐滴加至过夜培养的293T细胞培养孔中。在含有5%CO2的细胞温箱中,37℃培养48h后收细胞培养上清备用。
6.ELISA筛选具有结合活性的抗体
1)实验前一天96孔酶联板,包被1μg/mL的EBOV GP,每孔100μL包被;将包被的酶联板放入湿盒,4℃过夜。
2)实验当天用洗板机(BIO-TEK,405_LS)洗5次。
3)每孔加入100μL封闭液,室温下放置1小时。
4)洗板机洗5次。
5)加入100μL的转染细胞培养上清,室温静置1小时。
6)洗板机洗5次。
7)将HPR标记的羊抗人IgG二抗(Abcam,ab97225)以1:10000用稀释液进行稀释,每孔100μL加入到ELISA板对应孔中,室温孵育1小时。
8)洗板机洗5次。
9)每孔加入100μL的TMB单组份显色液,显色6min,室温避光,之后每孔加入50μL终止液终止反应。
10)用酶标仪上检测450-630nm处的OD值,保存记录原始数据。
结果:将13株单抗进行筛选,并对埃博拉GP的结合抗体进行特异性鉴定。有2株与埃博拉GP能够特异结合,包括4C1和4F1。图4显示了13株单抗的结合活性对照柱图。
7.4F1抗体序列说明
4F1抗体的轻链和重链的氨基酸序列描述如下:
所述轻链可变区的氨基酸序列如SEQ ID NO.1所示,轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.1的第27-32、50-52和89-97位氨基酸序列所示,轻链可变区的基因编码序列由SEQ ID NO.2所示,轻链恒定区的氨基酸序列如SEQ ID NO.3所示,轻链恒定区的基因编码序列由SEQ ID NO.4所示。
所述重链可变区的氨基酸序列如SEQ ID NO.5所示,重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.5的第26-33、51-57和96-107位氨基酸序列所示,重链可变区的基因编码序列由SEQ ID NO.6所示,重链恒定的氨基酸序列如SEQ ID NO.7所示,重链恒定区的基因编码序列由SEQ ID NO.8所示。
8.表达质粒构建与抗体制备
对4F1构建表达质粒,进行单抗的表达制备。方法如下:
1)将4F1H和4F1K线性表达框全长基因用EcoRI(NEB,R3101)和NotI(NEB,R3189)双酶切,连接至pcDNA3.4表达质粒。
2)取pcDNA3.4-4F1H和pcDNA3.4-4F1K各15μg,转染至30mL Expi293体系(Life,A14524)中,125rpm,5%CO2培养72h。
3)3000×g,离心10min收取表达上清,经0.22μm针头滤器抽滤后,采用rProtein A亲和纯化。
4)用PBS对收集的抗体进行换液,然后用BCA蛋白定量试剂盒(ThermoScientific,23225)测定抗体浓度。
实施例2.ELISA检测抗体结合活性
1)实验前一天96孔酶联板,包被1μg/mL的EBOV GP、BDBV GP、SUDV GP和RESTV GP,每孔100μL包被。将包被的酶联板放入湿盒,4℃过夜。
2)实验当天用洗板机洗5次。
3)每孔加入100μL封闭液,室温下放置1小时。
4)洗板机洗5次。
5)首孔加入150μL浓度为10μg/mL的4F1单抗,其余孔加入100μL的稀释液。从首孔吸出50μL加入到次孔,以此类推,按1:3梯度稀释每孔终体积为100μL。室温静置1小时。
6)洗板机洗5次。
7)将HPR标记的羊抗人IgG二抗以1:10000用稀释液进行稀释,每孔100μL加入到ELISA板对应孔中,室温孵育1小时。
8)洗板机洗5次。
9)每孔加入100μL的TMB单组份显色液,显色6min,室温避光,之后每孔加入50μL终止液终止反应。
10)用酶标仪上检测450-630nm处的OD值,保存记录原始数据。
结果:4F1单抗与EBOV GP具有良好的结合活性,EC50值为0.0057μg/mL。4F1与BDBVGP、SUDV GP和RESTV GP弱结合或不结合,对埃博拉病毒不具有广谱结合活性,说明其结合表位在几种埃博拉病毒GP上不保守(检测结果参见图5)。
实施例3.假病毒中和实验评价4F1中和活性
包装HIV骨架的EBOV假病毒,在体外评价4F1的中和活性,方法如下:
1)用DMEM培养基稀释4F1单抗,96孔细胞培养板首孔加入75μL浓度为100μg/mL的抗体稀释液,其余孔加入50μL的DMEM培养基。
2)从首孔吸取25μL液体加入次孔,混匀,以此类推,按1:3倍比稀释,每孔终体积为50μL。
3)将假病毒按1:5用DMEM培养基稀释(使对照孔荧光素读值控制在20000~100000之间),加入至各抗体孔,每孔50μL。混匀,37℃孵育1h。
4)293T细胞计数,2×105cells/mL,每孔加入100μL。
5)将96孔细胞培养板放入37℃恒温箱中培养36~48小时。
6)取出细胞培养板,小心吸出培养液弃掉。各孔加入100μL细胞裂解液,震荡机上350rpm震荡15min。
7)3000rpm室温离心10min。
8)将荧光素酶检测***(Promega,E1501)的检测底物冻干剂和检测缓冲液混匀后,充盈GLOMAX 96MICROPLATE LUMINOMETER(Promega)检测管路。
9)吸取20μL裂解上清读值,读取荧光值,计算抗体对细胞的保护率。
结果:与对照抗体相比,4F1在体外可有效地中和EBOV假病毒。4F1中和活性随着抗体浓度的升高而增强,在1μg/mL的浓度下即可对EBOV实现100%的保护(检测结果参见图6)。
实施例4.截短型抗原分析4F1结合区域
4F1呈现出良好的体外中和活性,希望通过构建截短型GP来分析其大致的结合区域。除了文献中常见的GPdTM、GPdM、GP1、sGP和GPcl外,根据GP结构特点和分析目标,还设计构建了GP33-310;463-558、GP33-227、GP33-158、GP95-295、GP158-295和GP227-295。GP33-310;463-558是在GPdM的基础上去掉了后面的七肽重复区;GP33-227是在sGP的基础上去掉了聚糖帽;GP33-158包含了大部分的Base区和Head区;GP95-295相比sGP缺失了Base区;GP158-295相比sGP基本缺失了Base区和Head区;GP227-295包含了大部分的聚糖帽区。GPcl是在GPdM的基础上,经嗜热菌蛋白酶(thermolysin)切除聚糖帽得到的,不需构建表达质粒。各截短型GP的结构示意图如图7所示。
截短型GP分析4F1结合区域方法如下:
1)根据示意图,从GP全长基因中扩增各截短型GP基因片段,羧基端添加His6标签,将基因片段连接至pcDNA3.4表达质粒中。
2)各截短型GP在Expi293***中表达,NI-NTA纯化获得目的蛋白。
3)ELISA分析4F1对各截短型GP的结合活性,方法同实施例2所述。
结果:4F1与GPdM、sGP和GP1等几种截短型GP均能良好结合,EC50值分别为0.0069μg/mL、0.0039μg/mL和0.0078μg/mL,与GPdTM相差不大。虽然4F1与GPcl和GP95-295的结合活性相对GPdTM来说降低了约5倍,但结合活性相对良好,EC50值分别为0.032μg/mL和0.033μg/mL。因此,4F1的结合表位应该位于这些截短型GP所共有的区域,即95-190位氨基酸。4F1与各截短型抗原的结合活性检测见图8-图9。
实施例5.竞争实验
采用竞争结合ELISA分析4F1的抗原作用表位。用已知结合表位的MIL77-1/2/3和其余几株非中和抗体作为对照抗体,通过考察检测抗体与GP的结合是否会被同孵育的竞争抗体所阻断,来反映这些抗体的结合表位是否存在交叠。方法如下:
1)称取生物素(Thermo Scientific,21335)4mg,溶于2mL超纯水中,浓度为2mg/mL。
2)取抗体4F1、2E5、5D7、5G11、5B12、1B3、MIL77-1、MIL77-2、MIL77-3各200μg,体积控制在200μL左右。
3)以生物素比抗体为20:1的摩尔比标记抗体。将抗体和生物素混合,室温孵育1小时,用50kD的0.5mL离心过滤器换液,每次更换PBS约400μL,换液3次以上。
4)最后一次用PBS将过滤器中剩余的液体统一补齐至100μL左右(目的是使各抗体的浓度相近),测定抗体浓度。
5)96孔酶联板以1μg/mL的浓度包被GPdM,4℃包被过夜。
6)洗板机洗涤ELISA板,每孔加入100μL封闭液,37℃孵育1小时。
7)实验中检测抗体为生物素标记的抗体,竞争抗体为非生物素标记抗体。稀释液稀释竞争抗体至2.5μg/mL;稀释液稀释检测抗体至25ng/mL。
8)洗涤96孔板。各孔加入50μL的检测抗体和50μL的竞争抗体,每孔终体积100μL。
9)洗涤,链霉亲和素抗体(Thermo Scitntific,21126)以1:1000稀释,每孔加入100μL,37℃孵育1小时。
10)洗涤,每孔加入100μL TMB单组份显色液,避光显色6分钟,加入50μL终止液。
11)读取450-630nm OD值。
结果:竞争结合值小于30认为强竞争;大于30小于60认为弱竞争;大于60认为不竞争。各抗体自身之间很好地竞争结合,根据结果可将这些抗体分成四组。其中,结合于GP1亚基和结合于GP2亚基各两组。4F1与结合于GP2亚基的非中和抗体5B12、中和抗体MIL77-1和MIL77-2不存在竞争。4F1与结合于GP1亚基的除5G11外的对照抗体均存在或多或少的竞争现象,说明其结合表位与这些对照抗体的表位存在交叠或空间位阻。4F1与MIL77-3等对照抗体都结合于GP1亚基,且竞争结合,但4F1具有体外中和活性,而其他抗体则不具有中和活性,提示4F1具有与其他结合于GP2亚基的中和抗体组成鸡尾酒组合疗法的潜力(检测结果参见图10)。
实施例6.低pH下4F1与GPdM的结合活性检测
抗体与病毒颗粒表面的GP结合后,与病毒颗粒一起进入宿主细胞。在次级内体的酸性(pH约5.5)环境中,GP被酶切水解,进而与受体结合,促进病毒基因组的释放。为进一步考察在4F1与GP结合活性是否受酸性环境的影响,检测了体外在pH 7.5、pH 6.5、pH 5.5和pH 4.5的环境中4F1与GP的结合活性,ELISA方法同实施例2所述。
结果:在四种不同pH的环境中,4F1与GPdM的结合活性基本无变化。4F1与GP的结合稳定,不受次级内体低pH环境的影响,为其发挥中和作用提供了基础(检测结果参见图11)。
序列表
<110> 中国人民解放军军事科学院军事医学研究院
<120> 抗埃博拉病毒糖蛋白GP1亚基的单克隆抗体4F1及应用
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 107
<212> PRT
<213> Homo sapiens
<400> 1
Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Ala Ala Ser Ser Arg Ala Thr Gly Phe Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Gly Ser Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 105
<210> 2
<211> 321
<212> DNA
<213> Homo sapiens
<400> 2
gacatccaga tgacccagtc tccatcctcc ctgtctttgt ctccagggga aagagccacc 60
ctctcctgca gggccagtca gagtgttggc agttccttag cctggtacca gcagaaacct 120
ggccaggctc ccaggctcct catctatgct gcatccagca gggccactgg cttcccagac 180
aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag actggagcct 240
gaagattttg cagtgtatta ctgtcagcag tatggtggct cacctctcac tttcggcgga 300
gggaccaagg tggaaatcaa a 321
<210> 3
<211> 106
<212> PRT
<213> Homo sapiens
<400> 3
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
1 5 10 15
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
20 25 30
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
35 40 45
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Gly Thr
50 55 60
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
65 70 75 80
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
85 90 95
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105
<210> 4
<211> 318
<212> DNA
<213> Homo sapiens
<400> 4
actgtggctg caccatctgt cttcatcttc ccgccatctg atgagcagtt gaaatctgga 60
actgcctctg ttgtgtgcct gctgaataac ttctatccca gagaggccaa agtacagtgg 120
aaggtggata acgccctcca atcgggtaac tcccaggaga gtgtcacaga gcaggacagc 180
aaggacggca cctacagcct cagcagtacc ctgacgctga gcaaagcaga ctacgagaaa 240
cacaaagtct acgcctgcga agtcacccat cagggcctga gttcgcccgt cacaaagagc 300
ttcaacaggg gagagtgt 318
<210> 5
<211> 118
<212> PRT
<213> Homo sapiens
<400> 5
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Arg Ile Tyr
20 25 30
Asp Met His Trp Val Arg Gln Val Thr Gly Arg Gly Leu Glu Trp Val
35 40 45
Ser Ala Ile Gly Ser Ala Ser Asp Thr Tyr Tyr Arg Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Glu Asn Ala Lys Asn Ser Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Ala Gly Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95
Arg Ala Ser Phe Gly Glu Leu Met Phe Asp Leu Trp Gly Gln Gly Thr
100 105 110
Leu Val Thr Val Ser Ser
115
<210> 6
<211> 354
<212> DNA
<213> Homo sapiens
<400> 6
gaggtgcagc tggtggagtc tgggggaggc ttggtacagc ctggggggtc cctgagactc 60
tcctgtgcag cctctggatt cagcttcagg atctacgaca tgcactgggt ccgccaagtt 120
acagggagag gtctggaatg ggtctcagct attggttctg ctagtgacac atactatcga 180
gactccgtga agggccgatt caccatctcc agagaaaatg ccaagaactc cttgtatctg 240
caaatgaaca gcctgagagc cggggacacg gctgtgtatt actgtgcaag agcgagtttc 300
ggggagttaa tgtttgactt atggggccag ggaaccctgg tcaccgtctc ctca 354
<210> 7
<211> 330
<212> PRT
<213> Homo sapiens
<400> 7
Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Val Lys Thr Lys Pro Arg Glu
165 170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Pro
180 185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
225 230 235 240
Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330
<210> 8
<211> 990
<212> DNA
<213> Homo sapiens
<400> 8
gcgtcgacca agggcccatc ggtcttcccc ctggcacctt cctccaagag cacctctggg 60
ggcacagcgg ccctgggctg cctggtcaag gactacttcc ccgaaccggt gacggtgtcg 120
tggaactcag gcgccctgac cagcggcgtg cacaccttcc cggctgtcct acagtcctca 180
ggactctact ccctcagcag cgtggtgacc gtgccctcca gcagcttggg cacccagacc 240
tacatctgca acgtgaatca caagcccagc aacaccaagg tggacaagaa agttgagccc 300
aaatcttgtg acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga 360
ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct 420
gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg 480
tacgtggacg gcgtggaggt gcataatgtc aagacaaagc cgcgggagga gcagtacaac 540
agcacgtacc gtgtggtcag cgtcctcacc gtcccgcacc aggactggct gaatggcaaa 600
gagtacaagt gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 660
aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggatgag 720
ctgaccaaga accaggtcag cctgacctgc ctggtcaagg gcttctatcc cagcgacatc 780
gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg 840
ctggactccg acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg 900
cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 960
cagaagagcc tctccctgtc tccgggtaaa 990
Claims (9)
1.一种抗埃博拉病毒糖蛋白GP1亚基的单克隆抗体,其特征在于,所述抗体轻链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.1的第27-32、50-52和89-97位氨基酸序列所示,所述抗体重链可变区的CDR1、CDR2和CDR3的氨基酸序列分别如SEQ ID NO.5的第26-33、51-57和96-107位氨基酸序列所示。
2.根据权利要求1所述的单克隆抗体,其特征在于,所述抗体轻链可变区的氨基酸序列如SEQ ID NO.1所示,所述抗体重链可变区的氨基酸序列如SEQ ID NO.5所示。
3.根据权利要求2所述的单克隆抗体,其特征在于,所述抗体轻链恒定区的氨基酸序列如SEQ ID NO.3所示,所述抗体重链恒定区的氨基酸序列如SEQ ID NO.7所示。
4.一种编码权利要求1-3任一所述单克隆抗体轻链和重链的多核苷酸,其特征在于,编码所述单克隆抗体的轻链可变区的多核苷酸的序列由SEQ ID NO.2所示,编码所述单克隆抗体的重链可变区的多核苷酸的序列由SEQ ID NO.6所示。
5.根据权利要求4所述的多核苷酸,其特征在于,编码所述抗体的轻链恒定区的多核苷酸的序列由SEQ ID NO.4所示,编码所述抗体的重链恒定区的多核苷酸的序列由SEQ IDNO.8所示。
6.一种含有权利要求5所述编码单克隆抗体重链和轻链的多核苷酸的线性表达框。
7.一种含有权利要求6所述线性表达框的宿主细胞,其特征在于,所述细胞为293T细胞。
8.权利要求1-3任一所述的单克隆抗体在制备埃博拉病毒病治疗药物中的应用。
9.根据权利要求8所述的应用,其特征在于,所述单克隆抗体作为埃博拉病毒病鸡尾酒疗法制剂中的组分使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811310292.3A CN111138527B (zh) | 2018-11-06 | 2018-11-06 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811310292.3A CN111138527B (zh) | 2018-11-06 | 2018-11-06 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111138527A CN111138527A (zh) | 2020-05-12 |
CN111138527B true CN111138527B (zh) | 2021-07-30 |
Family
ID=70515749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811310292.3A Active CN111138527B (zh) | 2018-11-06 | 2018-11-06 | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111138527B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113968907B (zh) * | 2020-07-22 | 2023-05-26 | 中国人民解放军军事科学院军事医学研究院 | 具有中和活性的抗尼帕病毒单克隆抗体及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864904A (zh) * | 2014-03-04 | 2014-06-18 | 中国人民解放军军事医学科学院生物工程研究所 | 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用 |
CN105087497A (zh) * | 2015-08-21 | 2015-11-25 | 浙江大学医学院附属第一医院 | 杂交瘤细胞株zjeb8-01、抗埃博拉病毒gp蛋白单克隆抗体及其制备和应用 |
CN107033242A (zh) * | 2017-04-16 | 2017-08-11 | 中国人民解放军军事医学科学院生物工程研究所 | 一种人源抗埃博拉病毒包膜糖蛋白的单克隆抗体及应用 |
CN107667115A (zh) * | 2015-01-26 | 2018-02-06 | 瑞泽恩制药公司 | 针对埃博拉病毒糖蛋白的人抗体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9346875B2 (en) * | 2013-06-03 | 2016-05-24 | Albert Einstein College Of Medicine, Inc. | Therapy for filovirus infection |
-
2018
- 2018-11-06 CN CN201811310292.3A patent/CN111138527B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103864904A (zh) * | 2014-03-04 | 2014-06-18 | 中国人民解放军军事医学科学院生物工程研究所 | 基于埃博拉病毒包膜蛋白的抗原片段、截短体及应用 |
CN107667115A (zh) * | 2015-01-26 | 2018-02-06 | 瑞泽恩制药公司 | 针对埃博拉病毒糖蛋白的人抗体 |
CN105087497A (zh) * | 2015-08-21 | 2015-11-25 | 浙江大学医学院附属第一医院 | 杂交瘤细胞株zjeb8-01、抗埃博拉病毒gp蛋白单克隆抗体及其制备和应用 |
CN107033242A (zh) * | 2017-04-16 | 2017-08-11 | 中国人民解放军军事医学科学院生物工程研究所 | 一种人源抗埃博拉病毒包膜糖蛋白的单克隆抗体及应用 |
Non-Patent Citations (2)
Title |
---|
Potent neutralizing monoclonal antibodies against Ebola virus infection;20160516;《Sci.Rep.》;20160516;第6卷;1-15 * |
Systematic analysis of monoclonal antibodys against ebola viurs GP defines features that contribute to protection;Erica Ollmann Saphire;《CELL》;20180809;第174卷(第4期);938-952 * |
Also Published As
Publication number | Publication date |
---|---|
CN111138527A (zh) | 2020-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111303280B (zh) | 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用 | |
CN111592594B (zh) | 一种抗新型冠状病毒的单克隆抗体及其应用 | |
CN114044821B (zh) | 一种抗新冠病毒全人源广谱中和抗体zwc12及应用 | |
CN114031685B (zh) | 一种全人源抗新冠病毒中和抗体zw2g10及应用 | |
CN113735969B (zh) | 一种全人源抗新冠病毒广谱高中和活性单克隆抗体及应用 | |
CN107033242B (zh) | 一种人源抗埃博拉病毒包膜糖蛋白的单克隆抗体及应用 | |
CN113735970B (zh) | 一种抗新冠病毒全人源广谱中和抗体及应用 | |
CN111909265B (zh) | 一种结合破伤风毒素重链c端结构域的人源抗体及应用 | |
CN112076316B (zh) | 一种双抗体组合物及在制备covid-19治疗药物中的应用 | |
CN114605528B (zh) | 一种抗裂谷热病毒的单克隆抗体a38及应用 | |
CN113968908B (zh) | 具有广谱中和活性的抗亨尼帕病毒单克隆抗体及应用 | |
CN111848791B (zh) | 一种抗破伤风毒素的全人源中和抗体及应用 | |
CN111138527B (zh) | 抗埃博拉病毒糖蛋白gp1亚基的单克隆抗体4f1及应用 | |
CN113968907B (zh) | 具有中和活性的抗尼帕病毒单克隆抗体及应用 | |
CN114989291B (zh) | 一种靶向RBD的抗SARS-CoV-2全人源化单克隆抗体及应用 | |
CN111138529B (zh) | 具有独特结合位点的抗ebov的gp2亚基的单克隆抗体5e1 | |
CN111138531B (zh) | 特异结合于ebov的gp1亚基的单克隆抗体8f9及应用 | |
CN111138528B (zh) | 特异性结合于埃博拉病毒糖蛋白聚糖帽的单克隆抗体5a8 | |
CN111138530B (zh) | 具有独特结合位点的抗ebov的单克隆抗体5e9及应用 | |
CN110903386B (zh) | 一种高中和活性抗基孔肯雅热的全人源单克隆抗体及应用 | |
CN111138526B (zh) | 一种抗埃博拉病毒糖蛋白gp2亚基的单克隆抗体2g1及应用 | |
CN114989292B (zh) | 一种抗SARS-CoV-2全人源化单克隆抗体及应用 | |
CN110922478A (zh) | 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用 | |
CN114634565B (zh) | 一种抗裂谷热病毒的单克隆抗体e44及应用 | |
CN108299559A (zh) | Zaire型埃博拉病毒检测抗体及其制备方法及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |